A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Rodabe Navroze Amaria, Axel Hauschild, Michael Lowe, Janis M. Taube, Adil Daud, Thach-Giao Truong, Sarah A. Weiss, Ankit Mangla, Tapan Miyani, Deidre Williams, Fang Fang, Shuquan Chen, Mark Salvati, Israel Lowy, Rossella Marullo, Matthew G. Fury, Karl Lewis, Humberto Lara-Guerra
Institutions: The University of Texas MD Anderson Cancer Center, University Hospital Schleswig-Holstein, Emory University, Johns Hopkins University, University of California, San Francisco, Cleveland Clinic, Rutgers Cancer Institute, University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, Regeneron (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Regeneron Pharmaceuticals
OpenAlex ID: W4410819173